Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01435395
Title Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

gliosarcoma

high grade glioma

glioblastoma

Therapies

Bevacizumab + Bortezomib + Temozolomide

Age Groups: adult
Covered Countries USA


No variant requirements are available.